A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and its severe form, toxic epidermal necrolysis (TEN), are rare but life-threatening cutaneous adverse reactions to drugs, especially to allopurinol, carbamazepine, lamotrigine, phenobarbital, phenytoine, sulfamethoxazole, oxicam and nevirapine. Recently, a strong association between carbamazepine and allopurinol induced SJS or TEN has been described with respectively, HLA-B*1502 and HLA-B*5801 in a Han Chinese population from Taiwan and other Asian countries. OBJECTIVE: The objective is to further investigate the relationship between SJS/TEN and HLA-B in a large number of patients in a European population. METHODS: HLA-B genotyping was performed on 150 patients included in a European study (RegiSCAR) of SJS and TEN. We focused on patients related to 'high-risk' drugs including: 31 cases related to allopurinol, 28 to sulfamethoxazole, 19 to lamotrigine and 14 to oxicam. RESULTS: Sixty-one percent of 31 allopurinol-induced SJS/TEN patients carried the HLA-B*5801 allele and the figure was 55% for 27 patients of European ancestry [odds ratio=80 (34-187)], (P<10(-6)) as previously observed in Han Chinese. For other drugs, two rare alleles showed a weaker association with SJS/TEN in a limited number of patients: B*38 for sulfamethoxazole or lamotrigine-related patients, and B*73 for oxicam. CONCLUSION: At variance with prior results in Asia, this study shows that even when HLA-B alleles behave as strong risk factors, as for allopurinol, they are neither sufficient nor necessary to explain the disease. Further investigations are necessary to delineate the exact role of the HLA region in SJS/TEN, and to look for other associations in other regions of the genome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
In the citing paper
“Furthermore, several studies have found that HLA-B*58:01, which was expressed relatively more frequently in the Chinese population (10–15%) compared to the Caucasian population (0.8%) is strongly associated with allopurinol sensitivity and cause Stevens–Johnson Syndrome [104].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [104]
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807 · cited 1×
“Adverse reactions to drugs are important causes of morbidity and even of death in developed countries [ 1 ].”
BackgroundA marker for Stevens–Johnson syndrome
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004) · Nature · doi:10.1038/428486a · Cited by 1,753
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Self-citationMallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380 · cited 1×
“In the previous years growing interest focused on the role of HLA in severe drug reactions, which was initiated by the demonstration that HLA-B*5701, was strongly associated with hypersensitivity to the anti-HIV medication abacavir [ 16 ,17].”
BackgroundHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
Hung, S.-I., Chung, W.-H., Liou, L.-B., Chu, C.-C., Lin, M., Huang, H.-P., Lin, Y.-L., Lan, J.-L., Yang, L.-C., Hong, H.-S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409500102 · Cited by 1,284 · cited 4×
“In Taiwan the carrier prevalence of B*5801 was 20% in a control group [ 21 ].”
BackgroundInfluentialMockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Self-citationInhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005 · cited 1×
“The initial events triggering the immune reaction remain to be identified [ 10 ].”
BackgroundInhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08158-8 · Cited by 807
Delayed Drug Hypersensitivity Reactions
Pichler, W. J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-8-200310210-00012 · Cited by 735
Cited by
Items 301–400 of 660
Oussalah, A., Yip, V. L. M., Mayorga, C., Blanca, M., Barbaud, A. M., Nakonechna, A., Cernadas, J., Gotua, M., Brockow, K., Caubet, J., et al. (2020) · Allergy · doi:10.1111/all.14174 · Cited by 21
Kannabiran, C., Ueta, M., Sangwan, V., Rathi, V. M., Basu, S., Tokunaga, K., & Kinoshita, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-15965-7 · Cited by 21
Low, D., Nurul-Aain, A. F., Tan, W. C., Tang, J. J., Bakhtiar, M. F., Murad, S., Chang, C. C., Too, C. L., & Tang, M. M. (2020) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000408 · Cited by 21
Tan‐Koi, W. C., Sung, C., Chong, Y. Y., Lateef, A., Pang, S. M., Vasudevan, A. R., Aw, D. C., Lui, N. L., Lee, S. X., Ren, E. C., et al. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0016 · Cited by 21
Drug-induced epidermal necrolysis: Important new piece to end the puzzle
Roujeau, J., Bricard, G., & Nicolas, J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.10.015 · Cited by 21
Self-citationJun, I., Rim, J. H., Kim, M. K., Yoon, K. C., Joo, C.-K., Kinoshita, S., Seo, K. Y., & Ueta, M. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313263 · Cited by 20
A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China
Cheng, H. W., Yan, D., Zuo, X., Liu, J., Liu, W., & Zhang, Y. (2018) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000334 · Cited by 20
Nakatani, K., Ueta, M., Khor, S., Hitomi, Y., Okudaira, Y., Masuya, A., Wada, Y., Sotozono, C., Kinoshita, S., Inoko, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52619-2 · Cited by 20
Stevens-Johnson syndrome and toxic epidermal necrolysis
Oliveira, A., Sanches, M., & Selores, M. (2014) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2014.20066728 · Cited by 20
Safety of Urate-Lowering Therapies
Keenan, R. T. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.08.008 · Cited by 20
Detection of HLA-B*58:01 with TaqMan assay and its association with allopurinol-induced sCADR
Zhang, X., Ma, H., Hu, C., Yu, B., Ma, W., Wu, Z., Luo, X., Zou, H., & Guan, M. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0251 · Cited by 20
Definitions and mechanisms of drug hypersensitivity
Wedi, B. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.32 · Cited by 20
Tham, K. M., Yek, J. J. L., & Liu, C. W. (2024) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000531 · Cited by 19
Wong, C. S. M., Yeung, C. K., Chan, C. K. G., Yap, D. Y. H., Tang, S. C. W., Cheung, B. M. Y., Kwok, J., & Chan, H. H. L. (2021) · Archives of Dermatological Research · doi:10.1007/s00403-021-02258-3 · Cited by 19
Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity
Lee, M. T. M., Mahasirimongkol, S., Zhang, Y., Suwankesawong, W., Chaikledkaew, U., Pavlidis, C., Patrinos, G. P., & Chantratita, W. (2014) · Public Health Genomics · doi:10.1159/000366253 · Cited by 19
Gene polymorphisms and their role in epilepsy treatment and prognosis
Steinlein, O. K. (2010) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-010-0531-8 · Cited by 19
“…reasons allele carriers from low-frequency populations apparently have no increased risk for carbamazepine-related idiosyncratic drug reactions (Lonjou et al. 2008), an observation that raises unanswered questions about the mechanisms underlying the association with HLA-B-1502 in high-risk…”
BackgroundResultJia, Y., Su, T., Gu, Y., Li, C., Zhou, X., Su, J., Sun, P., Tang, J., Yang, L., Liu, G., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800237 · Cited by 18
“HLA-B*5801 were reported to be associated with allopurinol-induced Stevens-Johnson syndrome or drug-induced hypersensitivity syndrome (39, 40), and HLA-B*5701 were reported to be associated with abacavir-induced hypersensitivity reaction (41, 42).”
BackgroundWang, C., Lin, W., Chen, W., Chen, C., Lu, C., Hou, H., Hui, R. C., Wu, J. D., Chang, C., Chang, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.954596 · Cited by 18
“For example, HLA-B*58:01 is strongly associated with allopurinol-SCARs in Han-Chinese, Japanese, Korean, Thai, and European populations (Hung et al., 2005; Kaniwa et al., 2008; Lonjou et al., 2008; Tassaneeyakul et al., 2009; Kang et al., 2011; Ng et al., 2016); HLA-A*31:01 is associated with carbamazepine-DRESS among…”
BackgroundInfluentialFernández, T. D., Mayorga, C., Guéant, J., Blanca, M., & Cornejo-García, J. A. (2014) · Allergy · doi:10.1111/all.12304 · Cited by 18
“Thus, no HLA-B*1502 carriers were detected in a group of patients with SJS and controls in Japan (40), and a recently published paper carried out in Europeans also failed to detect this association (41).”
BackgroundInfluentialOkuläre Beteiligung bei Stevens-Johnson-Syndrom und toxisch epidermaler Nekrolyse
Chronopoulos, A., Mockenhaupt, M., & Pleyer, U. (2021) · Der Ophthalmologe · doi:10.1007/s00347-021-01351-2 · Cited by 18
Self-citationPersonalized Medicine for Hla-Associated Drug-Hypersensitivity Reactions
Bharadwaj, M., Illing, P. T., & Kostenko, L. (2010) · Personalized Medicine · doi:10.2217/pme.10.46 · Cited by 18
Lee, H. S., Ueta, M., Kim, M. K., Seo, K. Y., Sotozono, C., Kinoshita, S., & Yoon, K. C. (2015) · Cornea · doi:10.1097/ico.0000000000000708 · Cited by 18
Walker, L. E., Yip, V. L. M., & Pirmohamed, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00020-7 · Cited by 18
Immunogenetics of Drug-Induced Skin Blistering Disorders. Part I: Perspective
Bowman, C., & Delrieu, O. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.11 · Cited by 18
Dillman, K. M., Hawkins, A. M., Ragland, A. R., Wester, G. C., Greene, D. R., Varrassi, G., Moore, P. W., Behara, R., Ahmadzadeh, S., Siddaiah, H. B., et al. (2024) · Cureus · doi:10.7759/cureus.64654 · Cited by 17
Shu, C., Shu, D., Tie, D., Yu, M., Zhang, R., Wang, T., Dong, Q., Sun, Q., Mao, X., & Yan, Y. (2015) · International Journal of Dermatology · doi:10.1111/ijd.12651 · Cited by 17
Shim, J., Yun, J. J., Kim, M., Chung, S. J., Oh, J. H., Kang, D. Y., Jung, J., Cho, S., & Kang, H. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.11.039 · Cited by 17
Seth, I., Bulloch, G., Vine, M., Outmezguine, J., Seth, N., Every, J. D., & Daniell, M. D. (2022) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14045 · Cited by 17
RetractedDigging Up the Human Genome: Current Progress in Deciphering Adverse Drug Reactions
Su, S., Chung, W., & Chung, W. (2014) · BioMed Research International · doi:10.1155/2014/824343 · Cited by 17
Pharmacogenetics in Reproductive and Perinatal Medicine
Alfirevic, A., Alfirević, Ž., & Pirmohamed, M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.153 · Cited by 17
Human leucocyte antigen–adverse drug reaction associations: from a perspective of ethnicity
Ghattaoraya, G., Middleton, D., dos Santos, E. J. M., Dickson, R., Jones, A. R., & Alfirevic, A. (2017) · International Journal of Immunogenetics · doi:10.1111/iji.12304 · Cited by 17
“However, different HLA alleles (notably HLA-A*31:01) have been reported to be associated with CBZ-induced hypersensitivity in Caucasians (McCormack et al., 2011; Genin et al., 2014) indicating that ethnicity can influence risk profiles for a particular ADRs.”
BackgroundInfluentialPain Control in Third Molar Surgery
Araújo, R. Z., Júnior, A. A. C. P., Sigua-Rodríguez, E. A., Olate, S. M., Alves, L. C. F., & de Castro, W. H. (2016) · International journal of odontostomatology · doi:10.4067/s0718-381x2016000300003 · Cited by 17
Pharmacogenetics of toxic epidermal necrolysis
Lee, M. T. M., Chung, W., Wei, C.-Y., & Chen, Y.-T. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.495120 · Cited by 17
“This association did not decrease significantly when patients of European ancestry were analyzed (HLAB*5801 tested positive in 55% of the European patients; p value < 10, OR = 80, 95% CI = 34 -- 187) [37].”
BackgroundResultLi, X., Zhao, Z., & Sun, S. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160243 · Cited by 16
de Bustros, P., Baldea, A. J., Sanford, A. P., Joyce, C., Adams, W., & Bouchard, C. S. (2021) · Burns · doi:10.1016/j.burns.2021.08.009 · Cited by 16
Findings by an International Collaboration on SJS/TEN With Severe Ocular Complications
Ueta, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649661 · Cited by 16
“in Han Chinese- (18), European ancestry- (19), and Japanese patients (20).”
BackgroundEpidemiology and Risk Factors for Severe Delayed Drug Hypersensitivity Reactions
Gomes, E. R., Marques, M. L., & Regateiro, F. S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191105115346 · Cited by 16
Ito, A., Shimada, H., Ishikawa, K., Takeo, N., Hatano, Y., Katagiri, K., Kohno, K., Araki, Y., Terao, T., Kojima, H., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.018 · Cited by 16
Nicoletti, P., Bansal, M., Lefèbvre, C., Guarnieri, P., Shen, Y., Pe’er, I., Califano, A., & Floratos, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131038 · Cited by 16
“For instance, HLA-B 1502 and HLA-A 3101 are predictive markers for carbamazepine (CMZ)-induced SJS/TEN respectively in Asians [4,5] and Europeans [6], while HLA-B 5801 for allopurinol-induced SJS/TEN in both populations [7,8].”
BackgroundExploring recent advances in drugs severe cutaneous adverse reactions immunopathology
Cadot, R., Gery, P., Lenief, V., Nicolas, J., Vocanson, M., & Tauber, M. (2024) · Allergy · doi:10.1111/all.16316 · Cited by 15
Pharmacogenetics of Allopurinol—Making an Old Drug Safer
Lam, M. P. S., Yeung, C. K., & Cheung, B. M. Y. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.67 · Cited by 15
What’s new about oral treatments in Multiple Sclerosis? Immunogenetics still under question
Pistono, C., Osera, C., Boiocchi, C., Mallucci, G., Cuccia, M., Bergamaschi, R., & Pascale, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.025 · Cited by 15
Koomdee, N., Kloypan, C., Jinda, P., Rachanakul, J., Jantararoungtong, T., Sukprasong, R., Prommas, S., Nuntharadthanaphong, N., Puangpetch, A., Ershadian, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.866903 · Cited by 15
“, 2008), and European populations (56%) (Lonjou et al., 2008).”
Yang, F., Yang, Y., Zhu, Q., Chen, S., Fu, X., Yan, S., Meng, C., Ma, L., Sun, X., Xu, J., et al. (2015) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/jidsymp.2015.6 · Cited by 15
“Studies showed a strong association between HLA-B*58:01 and allopurinol-induced SJS/TEN (Kaniwa et al. , 2008; Lonjou et al. , 2008).”
BackgroundToxic epidermal necrolysis: an update
Tiwari, P. K., Panik, R., Bhattacharya, A., Ahirwar, D., & Chandy, A. (2013) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(13)60051-1 · Cited by 15
“Subsequently, a strong association between SJS/TEN and HLA-B*5801 was found in Japanese patients[34], Thai patients[32], and also, to a lesser extent (55% of cases), in patients of European origin[36].”
BackgroundSevere cutaneous adverse reactions: impact of immunology, genetics, and pharnacology
Harp, J., Kinnebrew, M. A., & Shinkai, K. (2014) · Seminars in Cutaneous Medicine and Surgery · doi:10.12788/j.sder.0059 · Cited by 15
Ueta, M. (2016) · Taiwan Journal of Ophthalmology · doi:10.1016/j.tjo.2016.06.001 · Cited by 15
Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics
Moyer, A. M., & Gandhi, M. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2573-6_2 · Cited by 15
Severe Cutaneous Adverse Reactions
Suran, L. (2013) · InTech eBooks · doi:10.5772/54820 · Cited by 15
Adverse cutaneous reactions to psychopharmaceuticals.
Lamer, V., Lipozenčić, J., & Turčić, P. (2010) · PubMed · Cited by 15
Allegra, A., Alonci, A., Penna, G., Russo, S., Gerace, D. G., Greve, B., D’Angelo, A., Catena, S., & Musolino, C. (2011) · Hematological Oncology · doi:10.1002/hon.1000 · Cited by 15
Gout Management in Patients With CKD: A Review
Ostrowski, R. A. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.04.020 · Cited by 14
Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis
Manson, L. E. N., van den Hout, W. B., & Guchelaar, H. (2021) · Pharmaceuticals · doi:10.3390/ph15010004 · Cited by 14
Pharmacogenomics of Drug Hypersensitivity
Kuruvilla, R., Scott, K., & Pirmohamed, M. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2022.01.006 · Cited by 14
Calligaris, L., Stocco, G., Iudicibus, S. D., Marino, S., Decorti, G., Barbi, E., Carrozzi, M., Marchetti, F., Bartoli, F., & Ventura, A. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000189202 · Cited by 14
Mockenhaupt, M. (2014) · Der Hautarzt · doi:10.1007/s00105-013-2694-y · Cited by 14
Self-citationLi, Y., Gibson, A., Saeed, H. N., Ashraf, M., Li, D., Ostrov, D. A., Krantz, M. S., Mallal, S. A., Alves, E., Chopra, A., et al. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.08.001 · Cited by 13
“However, HLA-B*38 is previously reported in a small European study [27].”
Pham, H. T., Tran, M. H., Hoang, T.-V. M., Nguyen, A., & Tran, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-16062-w · Cited by 13
“Among these, 5 studies did not have well-defined study bases for population-based control selection 10,13,16,35,36 , 12 studies inappropriately compared cases with population-based or genomic database controls without prior exposure to allopurinol 7,8,10–14, 16,25, 35– 37 .”
Pascart, T., Latourte, A., Chalès, G., Baumann, L., Solal, A. C., Ea, H., Flipo, R., Grichy, J., Letavernier, E., Lioté, F., et al. (2020) · Revue du Rhumatisme · doi:10.1016/j.rhum.2020.07.009 · Cited by 13
Neerukonda, V. K., & Stagner, A. M. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1893764 · Cited by 13
Capule, F. R., Tragulpiankit, P., Mahasirimongkol, S., Jittikoon, J., Wichukchinda, N., Alentajan-Aleta, L. T., Barit, J. J. G., Casanova-Gutierrez, J., Cabral‐Lim, L., Reyes, J. P. B., et al. (2021) · Pharmacogenomics · doi:10.2217/pgs-2020-0191 · Cited by 13
Das, S. K., Sampath, A., Zaman, S. U., Pati, A. K., & Atal, S. (2023) · Personalized Medicine · doi:10.2217/pme-2022-0126 · Cited by 13
Novedades en el diagnóstico de las toxicodermias
de la Torre, C., & Oh, H. J. S. (2013) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2012.11.016 · Cited by 13
Garcia, J. B. S., Ferro, L. S. G., Carvalho, A. B., da Rocha, R. M., & de Souza, L. M. L. (2010) · Brazilian Journal of Anesthesiology · doi:10.1016/s0034-7094(10)70053-2 · Cited by 13
Pharmacogenetics of hypersensitivity drug reactions
Negrini, S., & Becquemont, L. (2017) · Therapies · doi:10.1016/j.therap.2016.12.009 · Cited by 13
Lee, M. H., STOCKER, S. L., Williams, K. M., & Day, R. O. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120803 · Cited by 13
Caspofungin-Induced Severe Toxic Epidermal Necrolysis
Lee, M., Ni, Y.-W., Wang, C., Lee, C., & Wu, T.-W. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p053 · Cited by 13
Zespół toksycznej nekrolizy naskórka
Hinc-Kasprzyk, J., Polak-Krzemińska, A., & Ożóg-Zabolska, I. (2015) · Anestezjologia, Intensywna Terapia · doi:10.5603/ait.2015.0037 · Cited by 13
“Inne stwierdzone korelacje dotyczyły: HLA-B*5701 i abakawiru oraz HLA-B*3101 i karbamazepiny dla populacji europejskiej [21, 24, 33, 34].”
Baş, Z., & Uçakhan, Ö. Ö. (2019) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2019.13333 · Cited by 13
Prevalence and mortality rate of severe cutaneousadverse reactions at Siriraj Hospital
Limkobpaiboon, S. (2010) · Chulalongkorn Medical Journal · doi:10.58837/chula.cmj.54.5.7 · Cited by 13
“Although the incidence of severe cutaneous adverse reactions (SCAR) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug hypersensitivity syndrome (HSS) that are delayed type immune-mediated reaction((2)) are rare but they have significant impacts on patient’s well being because of high…”
BackgroundPharmacogenomics in dermatology: from susceptibility genes to personalized therapy
Pincelli, C., Pignatti, M., & Borroni, R. G. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00852.x · Cited by 13
Penna, G., Allegra, A., Romeo, G., Alonci, A., Cannavò, A., Russo, S., D’Angelo, A., Petrungaro, A., & Musolino, C. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.640347 · Cited by 13
HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US
Campbell, C. N., Krantz, M. S., Yu, A., Phillips, E. J. P., Collaborators, S.-J. S. E. N. (. S. S., Dodiuk‐Gad, R. P., Drucker, A. M., Ergen, E. N., Gangula, R., Goh, M., et al. (2025) · JAMA Dermatology · doi:10.1001/jamadermatol.2025.4240 · Cited by 12
Mifsud, N. A., Illing, P. T., Ho, R., Tuomisto, J. E. E., Fettke, H., Mullan, K. A., McCluskey, J., Rossjohn, J., Vivian, J. P., Reantragoon, R., et al. (2023) · Allergy · doi:10.1111/all.15814 · Cited by 12
“11,12,17 The immunopathology of ALP-induced cADRs has been elicit drug-induced T cell responsiveness.”
BackgroundKawai, Y., Hitomi, Y., Ueta, M., Khor, S., Nakatani, K., Sotozono, C., Kinoshita, S., Nagasaki, M., & Tokunaga, K. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00171-2 · Cited by 12
Drug Eruptions Induced by Allopurinol Associated with HLA-BFNx015801
Sang, H., Zeng, M., Zhang, M., Liu, F., Yan, W., & Kong, Q. (2015) · Indian Journal of Dermatology Venereology and Leprology · doi:10.4103/0378-6323.148566 · Cited by 12
Current Japanese regulatory situations of pharmacogenomics in drug administration
Ishiguro, A., Toyoshima, S., & Uyama, Y. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.4.505 · Cited by 12
Liu, X., Sun, J., Yu, H., Chen, H., Wang, J., Zou, H., Lu, D., Xu, J., & Zheng, S. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.7 · Cited by 12
Kang, X., Chen, R., Han, M. S., Liu, Z., Liu, J., Dai, P., Chen, C., & Wang, H. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.160 · Cited by 12
The study of severe cutaneous drug hypersensitivity reactions from a systems biology perspective
Perkins, J. R., Ayuso, P., Cornejo-García, J. A., & Ranea, J. A. G. (2014) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000076 · Cited by 12
“Most genetic studies of SJS/TEN induced by allopurinol have found associations with the HLA-B 5801 allele in both Asian [29–31] and European populations [32].”
BackgroundGauging Reactive Metabolites in Drug-Induced Toxicity
Eno, M. R., & Cameron, M. D. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140826113520 · Cited by 12
“Other studies have demonstrated an immune component in serious drug-induced skin toxicity from compounds that are known to generate reactive metabolites or otherwise covalently modify proteins [340].”
HLA and the Pharmacogenomics of Drug Hypersensitivity
White, K. D., Gaudieri, S., & Phillips, E. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00021-9 · Cited by 12
Jung, J., Kim, J., Yoon, S., Cho, S., Park, S., & Kang, H. (2014) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.233.95 · Cited by 12
Nguyen, H. T., Hurwitz, R. S., DeFoor, W. R., Minevich, E. A., McAdam, A. J., Mortensen, J. E., Novak-Weekley, S. M., Minnillo, B. J., & Elder, J. S. (2010) · The Journal of Urology · doi:10.1016/j.juro.2010.03.084 · Cited by 12
Żełabowski, K., Wojtysiak, K., Ratka, Z., Biedka, K., & Chłopaś‐Konowałek, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124103 · Cited by 11
“This suggests lower clinical significance of the HLA-B38:01 allele; compared to the previously mentioned HLA-B58:01, where, in the same study, 61% of affected individuals carried the allele and the odds ratio reached 80 [119].”
The Genetics of Drug Hypersensitivity Reactions
Cornejo-García, J. A., Jurado‐Escobar, R., Doña, I., Doña, J., Agúndez, J. A. G., García‐Martín, E., Viguera, E., Blanca‐López, N., Canto, G., & Blanca, M. (2016) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0078 · Cited by 11
“Carbamazepine-Induced SJS-TEN One of the first studies demonstrating a strong association between a genetic marker, the HLA-B*1502 allele, and carbamazepine-induced SJS-TEN was performed in Han Chinese in 2004 [51] and has been further replicated by other studies performed in the same ethnic group [52,53] and in other…”
ResultShao, Z., Kyriakopoulou, L. G., & Ito, S. (2019) · Handbook of analytical separations · doi:10.1016/b978-0-444-64066-6.00014-9 · Cited by 11
Rufini, S., Ciccacci, C., Politi, C., Giardina, E., Novelli, G., & Borgiani, P. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.128 · Cited by 11
Büyüköztürk, S., Kekik, Ç., Gökyigit, A., Tezer, F. İ., Karakaya, G., Saygı, S., Dursun, A. B., Kırbaş, S., Tüfekçi, A., Sin, A. Z., et al. (2018) · European Annals of Allergy and Clinical Immunology · doi:10.23822/eurannaci.1764-1489.23 · Cited by 11
Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions
Zimmerman, D. E., & Dang, N. H. (2018) · Springer eBooks · doi:10.1007/978-3-319-74698-2_195-1 · Cited by 11
Role of Dermatology in Pharmacogenomics: Drug-Induced Skin Injury
Borroni, R. G. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.4 · Cited by 12
Magnetic Rotation of Monosodium Urate and Urinary Tract Stones for Clinical Treatment Applications
Takeuchi, Y., Sugawara, Y., Sugawara, T., & Iwasaka, M. (2014) · IEEE Transactions on Magnetics · doi:10.1109/tmag.2014.2322384 · Cited by 11
“possibility of side effects, physical stimulation methods such as those using magnetic fields are candidates for new medical treatments for gout as a substitute for pharmaceutical dosage [10]–[12].”
BackgroundMaggio, N., Firer, M., Zaid, H., Bederovsky, Y., Aboukaoud, M., Gandelman‐Marton, R., Noyman, I., Ekstein, D., Blatt, I., Marom, E., et al. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.873 · Cited by 11
Shanbhag, S. S., Koduri, M. A., Kannabiran, C., Donthineni, P. R., Singh, V., & Basu, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2020.607532 · Cited by 11
Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine
Chen, C., Wang, C., & Chung, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2265-0_3 · Cited by 11
Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
Mockenhaupt, M. (2009) · Springer eBooks · doi:10.1007/978-3-540-79339-7_9 · Cited by 11
Self-citationReacciones medicamentosas severas: Síndrome Stevens Johnson y síndrome DRESS
Torres, M., & Olmos, E. O. (2013) · Acta Médica Colombiana · doi:10.36104/amc.2013.289 · Cited by 11
HLA‐B*15 subtypes in Burmese population by sequence‐based typing
Kongmaroeng, C., Romphruk, A. V., Ruangwerayut, R., Paupairoj, C., Leelayuwat, C., Inoko, H., & Romphruk, A. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01281.x · Cited by 11
Opportunities and Challenges for Genome Sequencing in the Clinic
Cavalleri, G. L., & Delanty, N. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-394287-6.00003-3 · Cited by 12
Gonçalo, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.08.42 · Cited by 11
Metadata
- Authors
- Lonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., Schumacher, M., Roujeau, J.-C., Hovnanian, A., & Mockenhaupt, M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- University Medical Center Freiburg (DE)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Ben-Gurion University of the Negev (IL)
- University of Milan (IT)
- Leiden University Medical Center (NL)
- Innsbruck Medical University (AT)
- Université Paris-Est Créteil (FR)
- Corresponding author
- Roujeau, Jean-Claude
- Venue
- Pharmacogenetics and Genomics
- Published
- 2008-02
- Volume
- 18
- Issue
- 2
- Pages
- 99-107
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W2025161685
- Cited by
- 624
- References
- 28
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 23 · 2023: 26 · 2022: 29 · 2021: 34 · 2020: 23 · 2019: 31 · 2018: 36 · 2017: 40 · 2016: 26 · 2015: 48 · 2014: 43 · 2013: 43 · 2012: 40
- FWCI
- 33.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- Stevens-Johnson syndrome, toxic epidermal necrolysis, HLA-B*58:01, HLA-B*15:02, allopurinol, sulfamethoxazole, lamotrigine, oxicams, drug-induced skin reaction, European populations, genetic susceptibility
- MeSH terms
- Adult, Aged, Base Sequence, Female, Humans, Male, Middle Aged, Stevens-Johnson Syndrome, HLA-B Antigens, DNA Primers, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.